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A B S T R A C T
Background and purpose: To analyze plasma adiponectin kinetics in patients with ST-segment elevation
myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI) and its
association with coronary ﬂow reserve (CFR), an index of coronary microcirculatory function.
Methods: A total of 96 consecutive patients with the ﬁrst anterior STEMI treated by pPCI without heart
failure were included. CFR was assessed on the 7th day after pPCI. Plasma adiponectin was measured on
admission before pPCI, and on the 2nd and 7th day after pPCI.
Results: Adiponectin concentration was the highest on admission, declined to the lowest level on the 2nd
day, and rose on the 7th day remaining below admission values. Impaired coronary microcirculatory
function (CFR < 2) was observed in 41% of the patients. Adiponectin concentrations signiﬁcantly
positively correlated with CFR, and the strongest correlation was with the 2nd day adiponectin
(r = 0.489, p < 0.001). In multivariate models, adiponectin concentrations were independent predictors
of impaired CFR [on admission: odds ratio (OR) 0.175, conﬁdence interval (CI): 0.047–0.654, p = 0.010;
2nd day: OR 0.146, 95% CI: 0.044–0.485, p = 0.002; 7th day: OR 0.198, CI: 0.064–0.611, p = 0.005]. The
best power to predict impaired CFR was the 2nd day adiponectin. Delta values of adiponectin
(differences between adiponectin concentrations) did not correlate with CFR.
Conclusions: In patients with the ﬁrst anterior STEMI treated by pPCI plasma adiponectin concentrations
before and after pPCI are strongly associated with CFR. Our results support the hypothesis that low
adiponectin, especially during the early post-pPCI period, carries the risk for impaired coronary
microcirculatory function in STEMI patients.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Restoration of adequate coronary microcirculatory function
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[1]. Patients with preserved CMF have better recovery of left
ventricular (LV) function with lesser LV remodeling and better
clinical outcomes [2]. Despite successful recanalization of the
infarct related artery (IRA) these aims are not reached in about 50%
of the patients [2]. Several mechanisms including microvascular
obstruction, ischemic injury, reperfusion injury, and individual
susceptibility to microvascular injury could alter local and reserved.
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impairment, despite successfully restored epicardial conductance
[3]. Modulations of these factors before, during, or soon after IRA
opening could have an impact on the clinical success of primary
percutaneous coronary intervention (pPCI) in myocardial salvage.
Adiponectin, an adipocyte-secreted hormone involved in
energy homeostasis, has broad [4], anti-inﬂammatory [5], anti-
oxidant [6], endothelium-, and myocardial-protective effects [7]
with potential positive regulatory function in coronary microcir-
culation [8–12]. Adiponectin protects heart from ischemia/
reperfusion injury in animal models [13]. A low level of plasma
adiponectin is a well-proven risk marker for coronary artery
disease [14,15], and its progression to unstable clinical presenta-
tion [16]. However, its role in patients with STEMI is controversial
[17–20], as well as the time of sampling after presentation, since it
has signiﬁcant dynamic changes in concentration during the acute
phase of myocardial infarction [21].
CMF after pPCI can be assessed by several techniques. Coronary
ﬂow reserve (CFR) of IRA can be assessed by transthoracic Doppler
echocardiography during adenosine infusion. In the absence of
signiﬁcant epicardial stenosis it reﬂects functional integrity of the
coronary microcirculation in the infarct region [22,23] and bears a
prognostic value after pPCI [24,25].
In this study we postulated that adiponectin is involved in the
response to microvascular injury and restoration of CMF in STEMI
after mechanical reperfusion. Accordingly, we have evaluated the
optimal time for adiponectin sampling to stratify the risk for
impaired CMF after pPCI in STEMI. The aim of this study was to
analyze the plasma adiponectin kinetics in relation to CFR in
patients with the ﬁrst anterior STEMI treated by pPCI.
Subjects and methods
Patient population
A total of 111 consecutive patients with the ﬁrst anterior STEMI
treated by pPCI were initially screened from the end of November
2009 to the beginning of December 2010. The inclusion criteria for
this prospective, single center, observational study included also
recanalization of left anterior descending artery (LAD) with visually
assessed residual stenosis <30%. The STEMI was deﬁned and treated
according to European Society of Cardiology guidelines [1]. The
exclusion criteria included: (1) inability or refusal to obtain written
informed consent; (2) overt heart failure (Killip class 3 or 4); (3)
inability to perform echocardiography examination with CFR
measurements with adenosine due to technically poor acoustic
window precluding satisfactory imaging of the left ventricle (LV) or
LAD ﬂow by Doppler, or states that are known as contraindications
for adenosine administration (chronic obstructive pulmonary
disease, 2nd or 3rd atrioventricular blocks); (4) signiﬁcant valvular
disease; (5) temporary or permanent pacemaker; (6) acute or
chronic inﬂammation or infection; and (7) a history of autoimmune,
malignant disease, liver, kidney, or thyroid diseases. Out of 111
initially screened patients, four patients were excluded due to
hemodynamic instability, seven patients died before they complet-
ed the study, one patient had tumor, one patient had poor acoustic
window, one patient refused to give consent to be enrolled in the
study, and one patient had retroperitoneal hematoma requiring
blood transfusion. Thus, the ﬁnal study population included 96
patients (mean age 59  12 years, men 73%). The Ethical Committee of
our hospital approved the study protocol. Anthropometric parameters
including weight and height were measured for all the patients, and
their body mass index was calculated as the ratio of weight to height
squared. Hypertension was deﬁned as systolic blood pressure
140 mmHg, a diastolic blood pressure 90 mmHg, or use of anti-
hypertensive treatment. Diabetes mellitus was deﬁned according toWorld Health Organization criteria [26]. Patients were considered
smokers if they smoked 1 cigarette/day at the time of admission or in
the preceding 12 months. Killip class on admission, depending on the
clinical manifestation of cardiac failure, was assessed (Killip 1, no heart
failure; Killip 2, S3 and/or basal lung crepitations; Killip 3, acute
pulmonary edema; and Killip 4, cardiac shock).
Blood sampling and biochemical analysis
When a diagnosis of STEMI was established and a decision to
perform pPCI was made, blood samples were obtained from
peripheral vein before starting intervention, and 4 h, 8 h, 12 h,
18 h, 24 h, 48 h (2nd day), and 168 h (7th day) after intervention.
Samples for adiponectin determination (before pPCI, on the 2nd
and 7th day) were centrifuged within 30 min and plasma was
stored at 80 8C. Plasma adiponectin levels were determined by
enzyme-linked immunosorbent assay (Mercodia1 AB, Uppsala,
Sweden). All samples were analyzed in duplicate, with a detection
limit of 1.25 ng/mL and intra- and inter-assay coefﬁcients of
variation of <5% and <6%, respectively. Blood samples for troponin
I (TnI), MB fraction of creatine kinase (CK-MB), N-terminal
pro-brain natriuretic peptide (NT-proBNP), and high-sensitive C-
reactive protein (hs-CRP) determination were allowed to coagulate
at room temperature for 30 min, and then centrifuged at 4000 rpm
for 10 min to obtain serum samples. Serum TnI and CK-MB were
measured by chemiluminescent microparticle immunoassay
(CMIA) on Architect i2000 System (Abbott, Abbott Park, IL, USA).
The serum levels of NT-proBNP were measured by Roche Cobas
6000 automated analyzer (Roche Diagnostics, Mannheim,
Germany). The serum hs-CRP concentrations were measured by
means of the immuno-turbidimetric test (Olympus Life and
Material Science Europe GmbH, Ennis, Ireland) on Olympus AU
400 analyzer. The lowest detectable level was 0.02 mg/L. Oxidized
low-density lipoprotein measurement in ethylenediaminetetraa-
cetic acid plasma was performed using Mercodia ELISA assay
(Mercodia). Other biochemical and hematologic measurements
involved the use of standard assays. The estimated glomerular
ﬁltration rate (eGFR) was calculated using abbreviated Modiﬁca-
tion of Diet in Renal Disease study formula [27].
Primary PCI
PCI was performed within 12 h from the onset of chest pain by
experienced interventionists. In all patients, a stent was success-
fully implanted in LAD. Angiographic Thrombolysis in Myocardial
Infarction (TIMI) ﬂow grade was evaluated as described previously
[28]. Slow ﬂow/no-reﬂow was deﬁned as TIMI  2 after PCI. All
patients and their angiograms were graded according to the
number of diseased coronary arteries. A coronary artery was
considered diseased if there was any obstructive lesion 70% in
diameter in that artery or one of its major branches (diameter
2.5 mm). Medication used in the acute phase included loading a
dose of clopidogrel 600 mg and aspirin 300 mg and intravenous
bolus of heparin before pPCI, followed by dual anti-platelet therapy
(clopidogrel or ticlopidine and aspirin) and statins in all patients.
Glycoprotein IIb/IIIa inhibitor, thrombectomy, and intracoronary
vasodilators were administered at the discretion of the interven-
tional cardiologist.
Transthoracic echocardiographic examination with the evaluation of
CFR
Transthoracic echocardiography with LAD CFR assessment was
performed on the 7th day after pPCI. This time point was chosen
based on previous data demonstrating dynamic changes in
coronary microcirculatory dysfunction in STEMI patients treated
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commercially available ultrasound machine (Acuson Sequoia
C256, Siemens Medical Solutions, Mountain View, CA, USA) and
3V2C multifrequency transducer using second harmonic technol-
ogy. Echocardiography included conventional resting 2D exami-
nation with measurements of LV end-diastolic and end-systolic
volume indices (LV EDVI and LV ESVI) on body surface area and
ejection fraction (EF) by Simpson’s methods, and evaluation of LAD
CFR as previously described [23,24]. In short, color Doppler
detection of the LAD ﬂow was obtained by a modiﬁed apical
approach using a 4-MHz transducer, with Doppler mapping
velocity range set between 16 and 24 cm/s. The systolic and
diastolic coronary ﬂow velocity spectra were obtained at baseline
and during the peak of hyperemia induced by i.v. adenosine
(0.14 mg/kg/min during 1 min). CFR was calculated as the ratio of
hyperemic to basal peak diastolic ﬂow velocities. All studies were
digitally recorded and stored for ofﬂine analysis by two experi-
enced examiners blinded to patient clinical data. The intraobserver
variability and interobserver variability for CFR LAD measure-
ments in our laboratory are <10% [23].
Statistical analysis
Normality distribution of analyzed continuous variables
was assessed with the Kolmogorov–Smirnov test. NormallyTable 1
Patient characteristics.
Clinical features All patients 
N (%) 96 (100) 
Age (years) 58.84  11.64 
Male (%) 73 
Body mass index (kg/m2) 26.32  3.79 
Waist circumference (cm) 96.44  10.80 
Hypertension (%) 65 
Diabetes (%) 26 
Hypercholesterolemia (%) 43 
Smokers (%) 35 
Time from the chest pain onset to balloon (min) 250 (165; 330) 
Killip class 1/2/3/4 on admission (%) 72/28/0/0 
Systolic blood pressure (mmHg) 117.50  15.35 
Diastolic blood pressure (mmHg) 75.74  10.39 
Heart rate (bmp) 79.76  16.13 
Echocardiography
Left ventricular end diastolic volume index (mL/m2) 60.8  20.0 
Left ventricular end systolic volume index (mL/m2) 32.5  14.9 
Left ventricular ejection fraction (%) 48.1  10.0 
Coronary ﬂow reserve 2.01  0.35 
Coronary ﬂow reserve < 2 (%) 41 
Angiographic ﬁndings
Single/multivessel disease (%) 63/37 
TIMI ﬂow grade 3 or 2 before pPCI (%) 19 
Infarct-related artery LAD (%) 100 
Procedural data
Number of implanted stents 1 (1; 1) 
Bare metal stent (%) 75 
Final minimal stent diameter (mm) 2.84  0.35 
Post-procedural data
Slow ﬂow/no-reﬂow after pPCI (%) 13 
MBG 0/1/2/3 (%) 22/43/20/15 
Medication during hospitalization
Glycoprotein IIb/IIIa antagonist (%) 35 
UFH/LMWH (%) 99 
ACE inhibitors/ARBs (%) 86 
Beta blockers (%) 89 
Diuretics (%) 31 
Statins (%) 97 
CFR, coronary ﬂow reserve; LAD, left anterior descending artery; pPCI, primary percuta
myocardial blush grade; UFH/LMWH, unfractionated heparin/low molecular weight hedistributed continuous variables are expressed as mean  SD,
and continuous variables that did not show normal distribution are
expressed as the median value and interquartile range (25th and
75th percentile). CFR was analyzed both as continuous variable
(with normal distribution) and categorical one, with values 2
considered as normal. Categorical data are shown as frequencies
and percentages. Related-samples Friedman’s two ways ANOVA by
ranks was used to test time-dependent changes of adiponectin
concentrations. Spearman’s rank correlation coefﬁcients were used
to assess the relationships between adiponectin concentrations
and other variables. To determine the best cut-off values for
adiponectin concentrations to predict impaired coronary microcir-
culation (i.e. CFR < 2), receiver-operating characteristic (ROC)
curves were generated and compared [30]. Cut-off values were
chosen according to Youden index, with respect to sensitivity and
speciﬁcity. Univariate binary logistic regression analysis was used
to evaluate the relationship between CFR and potential determi-
nants. Univariate predictors with p < 0.05 were reassessed in the
multivariate models and the method ‘‘enter’’ for the selection of
variables was used. Results are expressed as the odds ratios (ORs)
and their 95% conﬁdence intervals (CI) per one standard deviation
increment of each measure (facilitating comparisons of effect sizes
for individual measures). The statistical analyses were performed
using SPSS (SPSS version 20.0 Inc., Chicago, IL, USA), MedCalc for
Windows, version 12.5 (MedCalc Software, Ostend, Belgium) andCFR < 2 CFR  2 p
39 (41) 57 (59)
59.77  11.65 58.00  11.90 0.467
74 69 0.634
27.26  3.83 25.84  3.66 0.070
96.65  10.02 94.70  12.22 0.411
68 63 0.555
38 18 0.027
48 33 0.159
39 33 0.606
270 (180; 330) 259 (160; 330) 0.962
54/46/0/0 84/16/0/0 0.001
114.67  11.44 120.29  16.38 0.102
74.00  8.94 78.52  11.32 0.065
80.40  13.38 78.19  18.37 0.553
65.96  18.00 57.34  10.13 0.034
37.90  13.90 28.79  14.5 0.003
43.89  8.69 50.97  9.10 <0.001
1.68  0.22 2.23  0.22 <0.001
100 0
56/44 65/35 0.401
13 23 0.218
100 100 ns
1 (1; 1) 1 (1; 2) 0.079
77 74 0.719
2.84  0.43 2.84  0.33 1.00
23 5 0.010
15/57/21/7 25/37/20/18 0.525
46 28 0.069
97 100 0.224
82 90 0.297
99 90 0.966
33 30 0.716
97 97 0.794
neous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction; MBG,
parin; ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers.
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UT, USA). Statistical signiﬁcance was deﬁned as p < 0.05.
Results
Risk factors, clinical characteristics, interventional parame-
ters, and echocardiographic data are presented in Table 1 and
baseline biochemical variables in Table 2. The mean age of the
patients was 60 years and 73% were male. They were predomi-
nately nonsmokers (65%) and hypertensive (65%), 25% had
diabetes, 43% had hypercholesterolemia, and 63% had
BMI > 25 kg/m2. The median time from symptom onset to balloon
was 4.2 h. In all patients, successful recanalization of LAD was
done with visually assessed residual stenosis <30%. According to
CFR, the patients were divided into groups with impaired
(CFR < 2) and preserved (CFR  2) CMF. Patients with impaired
CFR had more frequently diabetes and slow ﬂow/no-reﬂow after
pPCI, higher Killip class on admission, and larger left ventricles
with lower ejection fractions compared to patients with preserved
CFR (Table 1). Patients with CFR < 2 had on admission higher
white blood cell and neutrophil counts, higher glucose level,
glycated hemoglobin (HbA1c), and triglycerides compared to
patients with CFR  2 (Table 2).
Time course of plasma adiponectin concentration during the
ﬁrst week after pPCI and changes in adiponectin concentrationsTable 3
Time course of plasma adiponectin levels and changes (D) in adiponectin concentration
between subgroups with impaired vs preserved coronary microcirculatory function.
All patients (n = 96) CFR <
Adipo 0 (mg/mL) 7.32 (5.10; 9.17) 6.06 (3
Adipo 2 (mg/mL) 4.04 (2.78; 6.01) 3.13 (1
Adipo 7 (mg/mL) 5.30 (3.87; 7.17)* 4.34 (2
D1 (mg/mL) 2.63 (4.04; 1.36) 2.62 (
D2 (mg/mL) 1.00 (0.54; 1.44) 0.91 (0
D3 (mg/mL) 1.41 (2.56; 0.61) 1.52 (
Adipo 0, adiponectin on admission; Adipo 2, adiponectin on day 2; Adipo 7, adiponectin
CFR, coronary ﬂow reserve.
* p < 0.001 for ANOVA between Adipo 0 vs Adipo 2 vs Adipo 7 within each group.
Table 2
Baseline laboratory parameters.
Parameter All patients (n = 96) 
Hemoglobin (g/L) 145.00  14.31 145
WBC count (109/L) 12.09  3.69 13
Neutrophil count (109/L) 9.42  3.37 10
Erythrocytes (1012/L) 4.54  0.45 4
Platelets (109/L) 230  71 235
Albumin (g/L) 43.26  5.14 43
Ferritin (mg/L) 163.91  110.47 165
Glucose (mg/dL) 158.02  56.94 182
HbA1c (%) 6.07  1.24 6
Uric acid (mg/dL) 289.57  72.74 293
Total cholesterol (mg/dL) 236.29  46.72 239
HDL cholesterol (mg/dL) 46.40  14.31 43
LDL cholesterol (mg/dL) 156.61  42.15 152
oxLDL (U/L) 110.44  52.77 123
Triglycerides (mg/dL) 168.28  129.31 205
Apo A1 (g/L) 1.45  0.27 1
Apo B (g/L) 1.12  0.28 0
eGFR (mL/min) 90.38  26.81 84
TnI (mg/L) 0.56 (0.10; 3.79) 1
CK-MB (mg/L) 7.90 (3.10; 37.10) 17
hs-CRP (mg/L) 3.46 (1.43; 8.00) 4
NT-proBNP (pg/mL) (ng/L) 242.55 (116.85; 774.58) 352
CFR, coronary ﬂow reserve; WBC, white blood cells; HbA1c, hemoglobin A1c; HDL, h
apolipoprotein; eGFR, estimated glomerular ﬁltration rate; TnI, troponin I; CK-MB, MB 
N-terminal pro-brain natriuretic peptide.(i.e. delta values; D) are presented in Table 3. D1 was deﬁned as
adiponectin level on day 2 – adiponectin at admission, D2 as
adiponectin on day 7 – adiponectin on day 2, and D3 as adiponectin
on day 7 – adiponectin at admission. Plasma adiponectin was the
highest on admission before pPCI, signiﬁcantly decreased and
reached the lowest level on the 2nd day (p < 0.001). On the 7th day
it increased in concentration, but still was below the values on
admission (p < 0.001). This time pattern was present in the whole
study group, and both in patients with preserved and impaired
CFR. However, at each time point patients with impaired CFR had
lower adiponectin concentrations (Table 3). There were no
signiﬁcant differences regarding the delta adiponectin values
between patients with impaired vs preserved CFR (Table 3).
Correlations between plasma adiponectin concentrations at
each time point and with delta values are presented in Table 4.
Correlations between plasma adiponectin levels and delta values
with biochemical and clinical parameters are presented in
Table 5.
The ROC curve analysis revealed the differences in sensitivity
and speciﬁcity of adiponectin concentrations over time to predict
impaired CFR (i.e. CFR < 2) and respective areas under curves
(AUC), and cut-off values are shown in Table 6. Pairwise
comparison of ROC curves demonstrated signiﬁcant difference
in AUC between adiponectin on admission vs 2nd day adiponectin
(95% CI: 0.016–0.172, p = 0.019), whereas difference between 2nds (median value, 25th; 75th percentile) in the whole study group and comparison
 2 (n = 39) CFR  2 (n = 57) p
.00; 7.58) 7.98 (6.41; 10.20) <0.001
.11; 4.04) 5.45 (4.04; 6.83) <0.001
.00; 5.50)* 6.77 (4.93; 7.63)* <0.001
3.94; 1.01) 2.63 (4.55; 1.82) 0.429
.47; 1.41) 1.01 (0.71; 1.48) 0.326
2.42; 0.42) 1.41 (2.82; 0.76) 0.521
 on day 7. D1 = Adipo 2  Adipo 0; D2 = Adipo 7  Adipo 2; D3 = Adipo 7  Adipo 0.
CFR < 2 (n = 39) CFR  2 (n = 57) p
.20  15.52 144.94  13.49 0.432
.02  3.95 11.45  3.39 0.039
.33  3.60 8.80  3.07 0.028
.51  0.55 4.56  0.42 0.358
  68 227  73 0.452
.76  6.77 42.91  3.64 0.443
.29  72.13 162.93  131.85 0.922
.88  71.53 143.24  38.59 0.001
.45  1.65 5.81  0.78 0.020
.70  75.90 286.68  71.02 0.655
.77  56.37 233.59  39.00 0.521
.70  15.47 47.56  14.69 0.229
.36  50.27 159.32  36.35 0.463
.00  48.2 101.21  54.32 0.072
.48  178.03 142.60  73.51 0.021
.42  0.29 1.46  0.25 0.462
.99  0.30 1.06  0.24 0.330
.02  31.03 94.73  22.78 0.061
.11 (0.13; 6.08) 0.35 (0.09; 2.71) 0.054
.00 (4.00; 47.80) 6.70 (2.15; 23.25) 0.087
.60 (1.40; 9.8) 3.10 (1.65; 6.25) 0.211
.72 (167.84; 679.62) 153.14 (75.85; 834.21) 0.114
igh-density lipoprotein; LDL, low-density lipoprotein; oxLDL, oxidized LDL; Apo,
fraction of creatine kinase; hs-CRP, high-sensitive C-reactive protein; NT-proBNP,
Table 4
Correlations between plasma adiponectin levels and changes in the adiponectin concentrations (D).
Parameter Adipo 0 Adipo 2 Adipo 7 D1 adipo D2 adipo D3 adipo
Adipo 0 – 0.741** 0.813** 0.705** 0.552** 0.609**
Adipo 2 0.741** – 0.889** 0.130 0.180 0.084
Adipo 7 0.813** 0.889** – 0.306** 0.508** 0.149
Values are presented as Spearman’s rank correlation coefﬁcients (r).
Adipo 0, adiponectin on admission; Adipo 2, adiponectin on day 2; Adipo 7, adiponectin on day 7. D1 = Adipo 2  Adipo 0; D2 = Adipo 7  Adipo 2; D3 = Adipo 7  Adipo 0.
** p < 0.01.
Table 5
Correlations between plasma adiponectin levels and changes in adiponectin concentration (D) with clinical and biochemical parameters.
Parameter Adipo 0 Adipo 2 Adipo 7 D1 adipo D2 adipo D3 adipo
CFR 0.363** 0.498** 0.430** 0.082 0.103 0.065
BMI 0.305** 0.340** 0.305** 0.092 0.080 0.050
Glucose 0.223* 0.231* 0.210* 0.114 0.238* 0.042
HDL cholesterol 0.411** 0.274** 0.323** 0.353* 0.314* 0.245*
Triglycerides 0.200* 0.273** 0.254* 0.018 0.100 0.090
Apo AI 0.287* 0.200* 0.225* 0.300* 0.234* 0.224*
hs-CRP 0.225* 0.285** 0.326** 0.036 0.176 0.044
CK-MB peak value 0.176 0.231* 0.177 0.055 0.053 0.013
TnI peak value 0.174 0.241* 0.198 0.076 0.099 0.023
Values are presented as Spearman’s rank correlation coefﬁcients (r).
Adipo 0, adiponectin on admission; Adipo 2, adiponectin on day 2; Adipo 7, adiponectin on day 7. D1 = Adipo 2  Adipo 0; D2 = Adipo 7  Adipo 2; D3 = Adipo 7  Adipo 0.
CFR, coronary ﬂow reserve; BMI, body mass index; HDL, high-density lipoprotein; Apo, apolipoprotein; hs-CRP, high sensitive C-reactive protein; CK-MB, MB fraction of
creatine kinase; TnI, troponin I.
* p < 0.05.
** p < 0.01.
Table 6
Time-dependent changes in sensitivity and speciﬁcity of adiponectin to predict impaired coronary ﬂow reserve (CFR < 2) and respective cut-off values, according to Youden
index.
Time AUC 95% CI (lower) 95% CI (higher) p Cut-off (mg/mL) Sens Spec Youden index J
Admission 0.750 0.652 0.833 0.001 7.60 79.49 57.89 0.3738
2nd day 0.844 0.756 0.940 <0.001 4.04 84.62 71.93 0.5677
7th day 0.791 0.697 0.868 <0.001 6.06 84.62 61.40 0.4602
Sens, sensitivity; Spec, speciﬁcity.
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signiﬁcance (95% CI: 0.004 to 0.109, p = 0.051).
Results of the univariate binary analysis demonstrated that
the predictors of impaired CFR (i.e. CFR < 2) were concentrations of
adiponectin on admission, on the 2nd and 7th day, slow ﬂow/no-
reﬂow after pPCI, LVEF, diabetes, blood glucose level, HbA1c
concentration, white blood cell and neutrophil counts, triglycer-
ides concentration, TnI concentration, and Killip class 2 on
admission (Table 7).
Multivariate logistic regression analysis was used to test the
signiﬁcant univariate predictors of impaired CFR (Table 8).
Adiponectin concentrations on admission, on the 2nd and 7th
day were tested in three separate models: A–C. In model A,
adiponectin concentration on admission and LVEF were indepen-
dent predictors of impaired CFR. In model B, 2nd day adiponectin
level and LVEF remained independent predictors. In model C,
adiponectin concentration on day 7 and LVEF were still indepen-
dent predictors for impaired CMF.
To detect a difference of 1SD for variables adiponectin on
admission, 2nd day adiponectin, 7th day adiponectin, slow
ﬂow/no-reﬂow, and LVEF, we had power of 100%, 100%, 99%,
100%, and 98.9%, respectively, at the 5% level with 0.41 event rate.
For variables diabetes, blood glucose, neutrophil count, and TnI,
power was 100%, 99%, 99%, 82%, and 70%, respectively (calculation
based on PASS software for logistic regression analysis).Discussion
This study, investigating time-dependent changes in plasma
adiponectin concentration in patients with the ﬁrst anterior STEMI
treated by pPCI, revealed several relationships. First, adiponectin in
our patient group decreased after pPCI reaching the lowest level on
the 2nd day, and increased in the following days to a level lower
than initial. Second, this is the ﬁrst study that in homogenous
STEMI patient population prospectively assessed the recovery of
coronary microcirculation in relation to serial changes in plasma
adiponectin concentration. The results indicate that low plasma
adiponectin concentrations on admission before pPCI, on days 2
and 7 after pPCI are independently from other potential factors
associated with impaired CMF.
Extensive experimental data demonstrated adiponectin’s vas-
culo- and cardioprotective effects mediated by its anti-inﬂamma-
tory, anti-oxidant, anti-apoptotic, and pro-regenerative properties.
Adiponectin is closely linked to coronary plaque volume [31].
Hypoadiponectinemia correlates with necrotic core lesions con-
tributing to increased risk of coronary plaque vulnerability [31].
However, the prognostic value of adiponectin concentration in
STEMI patients is still controversial. It depends, at least partly, on
timing of blood sample procurement after pPCI and on enrolment
of heart failure patients. Acute heart failure was suggested to per
se upregulate plasma adiponectin concentration [32,33]. Plasma
Table 7
Predictors of impaired coronary ﬂow reserve (CFR < 2) by univariate logistic
regression analysis.
Variable OR 95% CI p
Adipo 0 0.264 0.132–0.526 <0.001
Adipo 2 0.158 0.073–0.342 <0.001
Adipo 7 0.273 0.150–0.494 <0.001
D1 adipo 1.258 0.809–1.959 0.308
D2 adipo 1.093 0.723–1.653 0.672
D3 adipo 1.370 0.817–2.296 0.233
Age 1.159 0.767–1.750 0.484
Gender 1.100 0.441–2.742 0.838
Slow ﬂow/no-reﬂow 5.400 1.357–21.481 0.014
Ejection fraction 0.413 0.247–0.690 0.001
Diabetes 3.333 1.275–8.712 0.014
Glucose 2.449 1.403–4.276 0.002
HbA1c 1.800 1.035–3.131 0.037
eGFR 0.654 0.416–1.026 0.064
oxLDL 1.637 0.955–2.805 0.073
hs-CRP 1.434 0.948–2.169 0.088
NT-proBNP 0.884 0.679–1.1569 0.884
WBC count 1.558 1.013–2.395 0.043
Neutrophils count 1.612 1.041–2.494 0.032
Triglycerides 1.728 1.028–2.904 0.039
CK-MB 2.157 0.996–4.672 0.051
TnI 1.672 1.014–2.756 0.044
Killip class 2 4.571 1.767–11.825 0.002
Adipo 0, adiponectin on admission; Adipo 2, adiponectin on the 2nd day; Adipo
7, adiponectin on the 7th day; D1 adipo = Adipo 2  Adipo 1; D2 adipo = Adipo
7  Adipo 2; D3 adipo = Adipo 7  Adipo 0.
HbA1c, glycated hemoglobin; eGFR, estimated glomerular ﬁltration rate; oxLDL,
oxidized low-density lipoprotein; WBC, white blood cells; hs-CRP, high-
sensitive C-reactive protein; NT-proBNP, N-terminal pro-brain natriuretic
peptide; CK-MB, MB fraction of creatine kinase; TnI, troponin I.
Table 8
Predictors of impaired coronary ﬂow reserve (CFR < 2) by multivariate logistic
regression analysis.
Variable OR 95% CI p
Model A
Adipo 0 0.175 0.047–0.654 0.010
Slow ﬂow/no-reﬂow 0.620 0.063–6.144 0.683
Ejection fraction 0.239 0.079–0.725 0.012
Killip class 2 0.673 0.108–4.181 0.671
Diabetes 11.262 0.628–201.940 0.100
Glucose 1.075 0.367–3.148 0.895
HbA1c 0.674 0.202–2.245 0.520
WBC count 0.846 0.084–8.525 0.887
Neutrophils count 2.072 0.216–19.860 0.527
Triglycerides 1.581 0.673–3.714 0.293
TnI 1.426 0.505–4.028 0.503
Model B
Adipo 2 0.146 0.044–0.485 0.002
Slow ﬂow/no-reﬂow 0.316 0.018–5.453 0.428
Ejection fraction 0.205 0.056–0.747 0.016
Killip class 2 0.783 0.108–5.695 0.809
Diabetes 3.778 0.275–51.987 0.320
Glucose 1.250 0.407–3.839 0.696
HbA1c 0.858 0.246–2.996 0.810
WBC count 0.493 0.031–7.735 0.614
Neutrophils count 2.987 0.203–43.901 0.425
Triglycerides 0.237 0.695–4.352 0.237
TnI 1.741 0.479–6.327 0.400
Model C
Adipo 7 0.198 0.064–0.611 0.005
Slow ﬂow/no-reﬂow 0.369 0.025–5.436 0.468
Ejection fraction 0.247 0.077–0.790 0.018
Killip class 2 1.006 0.164–6.186 0.995
Diabetes 3.548 0.275–45.741 0.332
Glucose 1.702 0.597–4.847 0.319
HbA1c 0.619 0.192–1.994 0.422
WBC count 0.876 0.076–10.067 0.915
Neutrophils count 1.756 0.165–18.705 0.614
Triglycerides 1.587 0.672–3.751 0.292
TnI 1.360 0.431–4.286 0.600
Adipo 0, adiponectin on admission; Adipo 2, adiponectin on day 2; Adipo 7,
adiponectin on day 7. HbA1c, glycated hemoglobin; WBC, white blood cells; TnI,
troponin I.
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acute heart decompensation and decreased following treatment
[32]. Signiﬁcant hemodynamic instability in STEMI patients could
confound evaluation between plasma adiponectin concentrations
and CMF recovery after pPCI. In the current study, a homogenous
group of STEMI patients treated by pPCI was analyzed, excluding
those in Killip classes 3 and 4 (moderate to severe acute heart
failure).
We corroborate previous ﬁndings regarding the time-depen-
dent changes of adiponectin concentration in STEMI [21].
Adiponectin reaches the lowest levels between 24 h and 72 h
after pPCI, rises in the following days, but usually does not return to
the initial levels. Post-procedural decrement of plasma adiponectin
in STEMI could be attributed, at least partly, to the adiponectin
leakage from the vascular compartment damaged by ischemia–
reperfusion injury and its accumulation in the infarcted region, as
suggested by experimental studies [34]. In our study, the lowest
adiponectin concentration (day 2), moderately and inversely
correlated with the peak TnI and CK-MB values. Delta values of
adiponectin did not correlate with biomarkers of the infarct size,
but had strong correlation with the adiponectin concentration on
admission. These data suggest that the consumption of adipo-
nectin in STEMI patients is more related to plasma adiponectin
concentration on admission before pPCI, whereas the amount of
myocardial necrosis is more related to the lowest adiponectin
concentration reached after pPCI..
Previous data regarding adiponectin’s role in microcirculatory
homeostasis are scarce. They indicate a positive relationship
between adiponectin concentration and CFR in individuals with
normal coronary arteries [8,9] or females with microvascular
angina [10]. Adiponectin levels were also related to coronary
endothelial function, independently of metabolic syndrome in
non-diabetic patients with normal or mildly diseased coronary
arteries [11]. These data implicate adiponectin as a positive
regulator of CMF and CFR. Our ﬁndings extend these observationsand point to the association between plasma adiponectin
concentration and recovery of CMF in STEMI patients after pPCI,
independently from other potential factors. In the current study
all adiponectin concentrations, but none of the delta values of
adiponectin, correlated signiﬁcantly with CFR. These data suggest
that low adiponectin concentration before, during, and after
STEMI is associated with CFR impairment by itself, and that the
consumption of adiponectin is not essentially related with
impaired CMF. Adiponectin on the 2nd day post-pPCI (i.e. the
lowest concentration) had the best power to predict impaired CFR
(i.e. CFR < 2). Our results support the hypothesis that low
adiponectin, especially during the early post-pPCI period, carries
the risk for impaired CMF. The underlying mechanism of this
association is not clear. The low plasma adiponectin concentra-
tion can be just a bystander, a marker of impaired microcircula-
tion. However, the causal association between intravascular
adiponectin levels and recovery of CMF after pPCI is possible.
Although data from our study cannot provide unambiguous
answers to these questions, earlier experimental data demon-
strated positive inﬂuence of adiponectin on myocardial reperfu-
sion injury and microvascular damage [13]. In a preclinical pig
model of myocardial ischemia/reperfusion injury, a single
intracoronary administration of recombinant adiponectin
resulted in a reduction of myocardial infarct size and improved
LV function. This was parallel to a reduction of tumor necrosis
factor-alpha and an increase of interleukin-10 myocardial mRNA
D. Trifunovic et al. / Journal of Cardiology 65 (2015) 208–215214levels in tandem with lower apoptotic and enhanced anti-oxidant
activity [13].
Studies addressing the level of plasma adiponectin associated
with coronary microcirculatory impairment after pPCI in STEMI are
scarce. Kojima et al. [17] reported adiponectin level on admission
3.8 mg/mL as the best cut-off to predict major adverse clinical
events in males after STEMI and for female adiponectin’s decline
equally or more than 1.7 mg/mL. Adiponectin level 4.7 mg/mL at
day 7 after STEMI was the best cut-off to predict LV remodeling
[18]. In our study, the 2nd day adiponectin concentration
4.04 mg/mL has the best power to predict impaired CFR.
In several clinical studies, plasma adiponectin levels were
downregulated in association with cardiovascular risk factors,
including obesity, type 2 diabetes, hypertension, dyslipidemia, and
low-grade inﬂammation [35–39]. We conﬁrmed that previously
described adiponectin’s correlations with metabolic and inﬂam-
matory parameters are also present in the acute phase of
myocardial infarction. In the current study, adiponectin was
signiﬁcantly inversely related to BMI, triglycerides, glucose, and
hs-CRP levels and positively correlated with HDL cholesterol and
Apo A1 concentrations. However, in multivariate analysis,
adiponectin concentration remained a signiﬁcant predictor of
CFR even after adjustment for BMI, triglycerides, HDL cholesterol,
glucose, and hs-CRP levels. This might support previous ﬁndings
[40] that adiponectin’s effect on CFR could be independent of
glucose metabolism, insulin resistance, and obesity.
In the current study, in the multivariate models, LVEF was
constantly associated with CMF. The connection between impaired
CFR and impaired LV systolic function was described even in the
absence of coronary artery disease (in patients with non-ischemic
dilated cardiomyopathy) [41] and the importance of the increased
wall stress on CFR was emphasized [42]. In the current study,
impaired LV pump function, due to incomplete myocardial
reperfusion and/or reperfusion myocardial injury, could contribute
to the CMF impairment. However, vice versa is possible, i.e.
impaired CMF as a primary phenomenon after pPCI might be
involved in the development of the LV systolic impairment.
Study limitations
Possible limitations of the present study should be considered.
We assessed CMF using standard echocardiography and no invasive
or magnetic resonance imaging assessment was done. However, this
approach has been previously validated in our laboratory or
elsewhere [23,43] and compared to positron emission tomography
imaging [22]. In addition, Doppler echocardiography-derived CFR
has been shown to provide the prognostic information regarding LV
remodeling in reperfused anterior myocardial infarction [24,25].
Although magnetic resonance imaging would allow visual assess-
ment of microvascular obstruction in the infarct zone, IRA CFR allows
assessment not only of anatomical, but also of functional microvas-
cular integrity (i.e. vasodilatation capacity of microvasculature).
Only patients with the ﬁrst anterior STEMI were enrolled in
the current study. We selected this patient population inten-
tionally as potential beneﬁcial effects of adiponectin are likely
more important in large infarcts.
In this study, the total adiponectin level was determined. Since
it seems that high molecular weight multimer is the active form
[44], measurements of speciﬁc adiponectin isoforms might add
additional prognostic information beyond the assessment of the
total adiponectin levels.
Conclusion and potential future implications
In patients with the ﬁrst anterior STEMI treated by pPCI,
low plasma adiponectin concentration is an independent predictorof impaired CMF after procedure. Furthermore, our data as well as
data from experimental models [13] could encourage further
investigation, translational and clinical research on adiponectin’s
potential role in the recovery and reparation of coronary
microcirculation after pPCI.
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